Endocrine Abstracts

Macroprolactin, a circulating complex of monomeric prolactin together with an autoantibody, is commonly encountered in the course of endocrine investigations. It is generally agreed macroprolactin exhibits reduced bioactivity in vivo since individuals who harbour the complex do not demonstrate the classic clinical signs or symptoms characteristic of true hyperprolactinaemia. The aim of this study was to compare the relative potency of purified preparations of macroprolactin to...

Where screening for macroprolactin takes place, laboratories routinely rely on treatment of sera with polyethylene glycol (PEG) to distinguish macroprolactinaemia from true hyperprolactinaemia. However, PEG is incompatible with a number of common immunoassay platforms. The aim of this study was to assess the specificity and clinical utility of ultrafiltration as an alternative procedure for removal of bio-inactive prolactin IgG complexes such as macroprolactin from serum prior...

The importance of the differentiation between the apparent benign clinical condition of macroprolactinaemia and that of true hyperprolactinaemia, which requires therapy, is becoming widely recognised. Laboratories routinely rely on prolactin recoveries of less than 40 percent following treatment of sera with polyethylene glycol (PEG) to distinguish between the former and latter conditions. However, the 40 percent threshold employed is arbitrarily defined with little scientific...

Where screening for macroprolactin takes place, laboratories routinely rely on treatment of sera with polyethylene glycol (PEG) to distinguish macroprolactinaemia from true hyperprolactinaemia. However, PEG causes significant interference in some immunoassays and furthermore leads to co-precipitation of a variable amount of monomeric prolactin in addition to macroprolactin in treated sera. The aim of this study was to assess the specificity and clinical utility of alternative ...